<DOC>
	<DOCNO>NCT01757873</DOCNO>
	<brief_summary>This study compare Z160 placebo patient Postherpetic Neuralgia safety efficacy period 6 week .</brief_summary>
	<brief_title>Efficacy Safety Study Z160 Subjects With Postherpetic Neuralgia</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<criteria>Provide write informed consent . Either sex must age &gt; =18 year . Diagnosis PHN define presence pain area affect herpes zoster &gt; =6 month herpes zoster skin rash heal . Pain score last week &gt; =3 &lt; =8 PINRS If female , subject must postmenopausal , surgically sterilize &gt; =3 month screen visit , agree use 2 reliable method contraception childbearing potential . If male , subject must agree use condom . Willing able comply study procedure . Severe pain cause disease PHN . Neurolytic neurosurgical therapy PHN within 6 month screen ( subject receive spinal cord stimulator implant least 6 month screen eligible , setting need remain stable double blind study period without use magnet ) . History seizure , exclude pediatric febrile seizure , currently seizures . Stroke transient ischemic attack ( TIA ) &lt; =6 month screen visit . History current diagnosis schizophrenia bipolar disorder . Major depressive disorder generalize anxiety disorder &lt; =6 month screen visit . Subjects stable dos selective serotonin uptake inhibitor ( SSRIs ) depression ( major depressive disorder ) eligible study . Clinically significant alcohol substance dependency &lt; =1 year screen visit Imminent risk suicide ( positive response question 4 5 CSSRS ) suicide attempt within 6 month screen visit . Clinically significant condition , investigator 's opinion , may interfere study procedure compromise subject 's safety . Malignancy ( nonmetastatic basal squamous cell carcinoma skin carcinoma situ organ surgically remove &gt; 1 year screening recur ) . Condition know interfere absorption , distribution , metabolism , excretion drug . Illness within 30 day screen . History hypersensitivity calcium channel blocker . Multiple drug allergy Opioids ( dos exceed equivalent 15 mg oral morphine ) highdose capsaicin patch ( Qutenza ) &lt; =30 day screen visit . Moderate strong cytochrome P450 inducer within 30 day screen visit . Digoxin prohibit medication discontinue randomization . Other exclusion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>